01.11.2018 | Diabetes and Pregnancy (M-F Hivert and CE Powe, Section Editors) | Ausgabe 11/2018
Oral Agents for the Treatment of Gestational Diabetes
- Zeitschrift:
- Current Diabetes Reports > Ausgabe 11/2018
Wichtige Hinweise
This article is part of the Topical Collection on Diabetes and Pregnancy
Abstract
Purpose of Review
To review the current evidence of the safety and efficacy of the use of oral agents for treatment of gestational diabetes (GDM).
Recent Findings
The use of metformin and glyburide in pregnancy for treatment of GDM has dramatically increased since the early 2000s. Meta-analyses suggest that glyburide may increase the risk for large for gestational (LGA) infants and neonatal hypoglycemia. Conversely, metformin may potentially decrease rates of pregnancy-induced hypertension, LGA, neonatal hypoglycemia, and maternal weight gain. However, recent long-term offspring studies indicate a potential detrimental effect of metformin on fat mass that suggests an effect of such medication on fetal programming. While there have been several novel oral anti-diabetes medications brought to market in the past decade, there is minimal data to guide use and in particular data regarding long-term safety for the exposed offspring of treated women.
Summary
Most professional societies recommend insulin as first-line treatment of gestational diabetes after failure of lifestyle modification. Both metformin and glyburide cross the placenta and long-term safety data is limited. However, patient satisfaction is substantially higher with use of oral agents, and the current literatures suggest that metformin may reduce several common short-term adverse outcomes related to GDM.
